Boston Scientific (BSX) Slaughters It Shareholders Again

Health and Healthcare

Published: October 1, 2008 9:52 am

Last Updated: April 27, 2020 6:03 pm

Sad_clown The list of management screw-ups at Boston Scientific (BSX) is almost too long to number. It bought rival Guidant and added $7 billion in debt in the process. Some of Guidant’s products were not as good as due diligence might have indicated, so, by most measures BSX overpaid.

BSX then hit a big bump in the road for its largest product line which is drug-coated stents. The devices keep arteries open and clots away from the vessel walls. That was working fine until medical studies showed that stents were not as effective as believed. Some surveys even showed patients were better off having their chests cracked open for by-pass surgery, a fate not fit for a dog.

Now it turns out that part of the intellectual property used in the BSX stents does not even belong to the company. According to The Wall Street Journal, based on "a final judgment issued yesterday in federal court, Boston Scientific has to pay Johnson & Johnson for infringing a patent on a bare-metal stent." The price tag is over $700 million.

BSX shares are down almost 8% to $11.34 and investors have to be asking, for the tenth time, why the board keeps current management around.

Douglas A. McIntyre

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.